LONDON: British medicine group AstraZeneca on Thursday hiked its shareholder dividend citing optimism over its sturdy efficiency.
AstraZeneca “intends to increase the annualised dividend” by seven % to $3.10 per share, in a transfer which was “underlining the company’s confidence in its performance and cash generation”, it stated in a press release forward of its annual common assembly in London.
The information despatched the corporate’s share worth a couple of % greater in mid-morning offers on the British capital’s falling inventory market.
Astra board chairman Michel Demare added that the hike was “in line with our progressive dividend policy, which remains unchanged, and reflects the continuing strength of AstraZeneca’s investment proposition for shareholders”.
Thursday’s information comes after the group revealed in February that internet revenue nearly doubled to $6 billion final 12 months, with a robust most cancers division serving to offset a wipeout for gross sales of Covid therapies.
Revenue rose three % to just about $46 billion in 2023 in comparison with a 12 months earlier, though gross sales of Covid therapies slumped greater than $3.7 billion. Its oncology unit’s gross sales jumped 23 %.
AstraZeneca final month agreed to purchase US biopharma agency Fusion for up to $2.4 billion, in its newest enlargement into most cancers therapies.
Fusion is growing next-generation radiotherapy to deal with most cancers through exact focusing on that minimises injury to wholesome cells. Its methodology additionally allows entry to tumours which are arduous to succeed in utilizing commonplace radiation.
AstraZeneca “intends to increase the annualised dividend” by seven % to $3.10 per share, in a transfer which was “underlining the company’s confidence in its performance and cash generation”, it stated in a press release forward of its annual common assembly in London.
The information despatched the corporate’s share worth a couple of % greater in mid-morning offers on the British capital’s falling inventory market.
Astra board chairman Michel Demare added that the hike was “in line with our progressive dividend policy, which remains unchanged, and reflects the continuing strength of AstraZeneca’s investment proposition for shareholders”.
Thursday’s information comes after the group revealed in February that internet revenue nearly doubled to $6 billion final 12 months, with a robust most cancers division serving to offset a wipeout for gross sales of Covid therapies.
Revenue rose three % to just about $46 billion in 2023 in comparison with a 12 months earlier, though gross sales of Covid therapies slumped greater than $3.7 billion. Its oncology unit’s gross sales jumped 23 %.
AstraZeneca final month agreed to purchase US biopharma agency Fusion for up to $2.4 billion, in its newest enlargement into most cancers therapies.
Fusion is growing next-generation radiotherapy to deal with most cancers through exact focusing on that minimises injury to wholesome cells. Its methodology additionally allows entry to tumours which are arduous to succeed in utilizing commonplace radiation.
